Neurocrine Bio. (NBIX) PT Raised to $32 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Neurocrine Bio (NBIX) Price Target Raised at Deutsche Bank Following Positive Elagolix Phase 3
January 8, 2015 3:36 PM ESTDeutsche Bank Buy Neurocrine Bio. (NASDAQ: NBIX) price target of $35.00 (from $25.00). Yesterday it an AbbVie (NYSE: ABBV) announced positive top-line results from the first of two ongoing Phase 3 clinical trials designed to evaluate the efficacy and safety of elagolix in... More
AbbVie (ABBV) Issues Positive Top-Line Data from Two Elagolix Combo Phase 3s (NBIX)
January 8, 2015 8:02 AM ESTAbbVie (NYSE: ABBV) in cooperation with Neurocrine Biosciences, Inc. (Nsdaq: NBIX), announced positive top-line results from the first of two ongoing Phase 3 clinical trials, designed to evaluate the efficacy and safety of elagolix in premenopausal women with... More
